142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

307655
Collaborative Improvement and Innovation Network (CoIIN) to Reduce Infant Mortality: Regions IV and VI Results

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 1:30 PM - 1:50 PM

Ashley Hirai, PhD , Maternal and Child Health Bureau, HRSA/DHHS, Rockville, MD
Sara Donahue, DrPH, MPH , U.S. Health Division, Public Health and Epidemiology, Abt Associates, Cambridge, MA
Vanessa Lee, MPH , Maternal and Child Health Bureau, HRSA/DHHS, Rockville, MD
David de la Cruz, PhD, MPH , Maternal and Child Health Bureau, HRSA/DHHS, Rockville, MD
Reem Ghandour, DrPH, MPA , Maternal and Child Health Bureau, HRSA/DHHS, Rockville, MD
Katherine Flaherty, ScD , U.S. Health Division, Public Health and Epidemiology, Abt Associates, Cambridge, MA
Michael Lu, MD, MPH , Maternal and Child Health Bureau, HRSA/DHHS, Rockville, MD
Background: Launched in the 13 Regions IV/VI states in 2012, the Collaborative Improvement and Innovation Network (CoIIN) to Reduce Infant Mortality is a public-private partnership using the science of quality improvement and collaborative learning to achieve aims in common priority areas.  We examined progress toward shared goals: reducing early elective delivery and promoting smoking cessation, safe sleep, perinatal regionalization, and interconception care.

Methods:  Regions IV/VI CoIIN outcomes are measured using vital statistics, Medicaid, and PRAMS data. We reviewed outcome data submitted by states to evaluate progress toward aims, using state-level percent change in outcomes, comparing 2011 baseline data to the most recently available data.

Results: All 13 states have reduced rates of early elective delivery since 2011. The average change was -25% (range: -39% to -4%) and 5 states have achieved the aim of -33%.  Nine states have reduced rates of smoking during pregnancy by more than the -3% aim (overall average change: -6%; range: -22% to 15%).  Two states have increased the percent of very low birth weight infants born in hospitals with Level III+ neonatal intensive care units toward the 20% aim (overall average change: 2.7%; range: -2.7% to 14.2%).  Outcome data for safe sleep and interconception care are pending.

Conclusions: Regions IV/VI states have made remarkable progress toward common goals in at least two of five priority areas to reduce infant mortality and improve birth outcomes, demonstrating early successes of this collaborative partnership.  Process measures are being examined to identify successful strategies that hold promise for replication.

Learning Areas:

Conduct evaluation related to programs, research, and other areas of practice
Implementation of health education strategies, interventions and programs
Public health or related laws, regulations, standards, or guidelines
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
Describe the key features of the Regions IV/VI CoIIN to reduce infant mortality, including the role of data in tracking progress toward shared goals across the CoIIN. Identify successes in the Regions IV/VI CoIIN. Discuss data challenges and opportunities facing CoIIN and other public health quality improvement efforts that depend on real-time data to drive change

Keyword(s): Infant Mortality, Quality Improvement

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been a senior scientist in the federal government for 5 years conducting research on socioeconomic and racial/ethnic disparities in maternal and child health. I serve as a Bureau expert in advanced research/evaluation methods, GIS, and perinatal epidemiology, helping to inform planning, priority-setting, and evaluation for Bureau initiatives. Prior to federal service, I worked as an epidemiologist with the Hawai'i Health Department.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.